Clinical Trial Update: Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Y-90 radiotherapy alone or with Sorafenib in patients with hepatocellular carcinoma awaiting transplant; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Yttrium-90 microsphere therapy (Yttrium-90 microspheres)

Snippet

Sponsor: Northwestern University | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED